The Effect of Methylphenidate on Cognitive Abilities of Adults With Bipolar Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02020200|
Recruitment Status : Unknown
Verified December 2013 by Shalvata Mental Health Center.
Recruitment status was: Not yet recruiting
First Posted : December 24, 2013
Last Update Posted : December 24, 2013
|Condition or disease||Intervention/treatment||Phase|
|BD||Drug: MPH Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy Adults and Adults With Attention Deficit Hyperactivity Disorder (ADHD).|
|Study Start Date :||January 2014|
|Estimated Primary Completion Date :||December 2014|
Experimental: MPH or Placebo
MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg. Both participants and investigators will be blinded to when participant receives MPH or Placebo.
MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.
Other Name: Ritalin
- Cognitive function. [ Time Frame: Within 4 hours of intervention. ]Cognitive function will be measured by scores on several computerized neuro-psychological and decision making tasks: digit-span task, spatial working memory task, raven's progressive matrices, test of variable attention and the Iowa gambling task.
- Creativity abilities. [ Time Frame: Within 4 hours of intervention. ]Creativity will be measured by scores on two tests: the alternative use task and two subsets of the Torrance tests for creative thinking.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02020200
|Contact: Yael Lewis, MDfirstname.lastname@example.org|
|Contact: Yechiel Levkovitz, MD, PhD||+97297478644|
|Hod HaSharon, Israel|
|Principal Investigator:||Yechiel Levkovitz, MD, PhD||Shalavata MHC|